Parvaneh Hatami; Zeinab Aryanian; Hamed Nicknam Asl; Azadeh Goodarzi
Abstract
Since coronavirus disease 2019 (COVID-19) vaccines were approved without long-term monitoring, tracking their adverse effects appears to be necessary. Mucocutaneous adverse events are of great importance due to their visibility and the potential effect on inducing fear in patients leading to vaccine ...
Read More
Since coronavirus disease 2019 (COVID-19) vaccines were approved without long-term monitoring, tracking their adverse effects appears to be necessary. Mucocutaneous adverse events are of great importance due to their visibility and the potential effect on inducing fear in patients leading to vaccine hesitancy. We searched PubMed, Google Scholar, and Scopus in this regard, and all of the relevant papers published until June 28, 2021, were included if we could access their full texts. Moreover, we included some of our cases from Iran. We found various mucocutaneous manifestations after COVID-19 vaccination, including local injection site reactions (acute or delayed), urticarial lesions, pityriasis rosea-like rashes, angioedema, morbilliform rashes, pernio-like lesions, acrocyanosis, petechial/ purpuric/ecchymotic lesions, herpes flare-up, herpetiform rashes, oral erosive lesions, acral pustular rashes, erythema multiform, dermographism, herpes zoster, generalized pruritus, contact dermatitis, reaction to dermal fillers and non-specific rashes. We categorized them by their time of initiation (acute or delayed) and site of involvement (local injection site, remote area, or generalized). Delayed local reactions, local injection site reactions, urticarial lesions, and pityriasis rosea-like and morbilliform rashes were among the most common cutaneous adverse events. Dermatologists should be aware of these potential reactions to manage them properly, reassure patients, and encourage them to continue their vaccination.
Banihashemi Mahnaz; Javidi Zari; Khani Fatemeh; Ghiasi-Moghadam Taghi; Ghaffarzadegan Kamran; Hashemzadeh Sara
Volume 17, Issue 4 , 2014, , Pages 122-125
Abstract
Background: Pityriasis rosea (PR) is a common papulosquamousskin disorder that is suspected to have an infectious etiology.We aimed to study the role of human herpesvirus-6 (HHV-6) inthe pathogenesis of PR.Method: We used immunohistochemical (IHC) assays to detectHHV-6 in patients with PR. Fifty-one ...
Read More
Background: Pityriasis rosea (PR) is a common papulosquamousskin disorder that is suspected to have an infectious etiology.We aimed to study the role of human herpesvirus-6 (HHV-6) inthe pathogenesis of PR.Method: We used immunohistochemical (IHC) assays to detectHHV-6 in patients with PR. Fifty-one patients with PR and 35 ageand sex matched healthy control samples were enrolled in thestudy. The intensity and percentage of cell staining for HHV-6infection were evaluated and recorded.Result: The intensity of IHC staining was negative in 25 (49.01%)patients and 24 (68.58%) control samples while it was +1 in 6(11.77%) patients and 11 (31.42%) control samples, +2 in 4 (7.85%)patients and +3 in 16 (31.37%) of them. The incidence of moderateand intense staining for HHV-6 was significantly higher amongpatients with PR than the control group (P value < 0.01).Conclusion: We concluded that HHV-6 infection may play arole in some patients with PR. The rate of HHV-6 infection wassignificantly higher in PR patients than the control group.
Tehranchi-nia Zohreh; Rahimi Hoda
Volume 13, Issue 1 , 2010, , Pages 24-26
Abstract
Pityriasis rosea (PR) is an acute, self-limiting papulosquamous exanthem. A number of atypical variants of PR, regarding morphology and distribution of the lesions or severity of the symptoms, may be observed. Herein, we present the first case of atypical PR with hypopigmented lesions and a target-shape ...
Read More
Pityriasis rosea (PR) is an acute, self-limiting papulosquamous exanthem. A number of atypical variants of PR, regarding morphology and distribution of the lesions or severity of the symptoms, may be observed. Herein, we present the first case of atypical PR with hypopigmented lesions and a target-shape herald patch.
Ehsani Amir Hooshang; Toosi Siavash; Noormohamadpour Pedram; Hosseini Mahboubeh; Nazeman Leila
Volume 11, Issue 4 , 2008, , Pages 143-146
Abstract
Background: Pityriasis rosea is an inflammatory skin disorder with a known response to erythromycin. Considering similarities between erythromycin and azithromycin and lesser adverse effects of the latter, in a pilot study, we gave azithromycin to seven patients with pityriasis rosea and observed a noticeable ...
Read More
Background: Pityriasis rosea is an inflammatory skin disorder with a known response to erythromycin. Considering similarities between erythromycin and azithromycin and lesser adverse effects of the latter, in a pilot study, we gave azithromycin to seven patients with pityriasis rosea and observed a noticeable improvement. The aim of this study was to evaluate the efficacy of azithromycin in patients with pityriasis rosea.Methods: A double-blind, placebo-controlled clinical trial was performed in our clinic. Sixty patients over a period of 20 months were alternatively assigned to the treatment group or the placebo group. Patients in the treatment group received azithromycin, 250 mg/day, for 14 days. The response was categorized as complete response, partial response, or no response. All patients were followed up for 2 months.Results: Age at presentation, sex, and average duration of the disease were comparable in both groups. Complete response was observed in 19 patients (63.3 %) in the treatment group and two in the placebo group (p<0.0001).Conclusion: Oral azithromycin is effective in treating patients with pityriasis rosea.
SZ Famili; SM Dadkhah; S Ebrahim Zadeh
Volume 8, Issue 4 , 2005, , Pages 287-292
Abstract
Background and objective: Pityriasis rosea (PR) is a transient skin disease with a distinct appearance that is prevalent throughout the world and is more frequently seen in winter. Despite the reported epidemiological evidence, which account for an infective agent, this has not been proved, yet. This ...
Read More
Background and objective: Pityriasis rosea (PR) is a transient skin disease with a distinct appearance that is prevalent throughout the world and is more frequently seen in winter. Despite the reported epidemiological evidence, which account for an infective agent, this has not been proved, yet. This study was designed to determine the epidemiological features of PR in terms of age, gender, seasonal, and clinical features. Materials and Methods: In this survery, age, gender, time of referring, history of common cold, herald patch location, itching, as well as clinical manifestations among 251 patients with PR referred to dermatology clinic of Ghaem hospital in Mashhad from October 2001 to March 2003 were studied. Results: The female/male ratio was 2.07/1. The largest breakout was observed among patients aged between 15-30 years. The majority of them referred in autumn (32.9%) in October (14.7%), and November (11.5%). 17.9% of patients complained of itching and 7.6% of patients had purpuric PR lesions. One-hundred and forty-six (58.2%) patients complained of a history of common cold two months prior to admission and the percentage of patients with common cold was 65.8% in fall and 64.2% in winter. Conclusion: Because of a large breakout of disease in winter and a high rate of common cold in cold seasons, more research still is needed to prove the infective etiological factor, particularly viral factors.
M Akhyani; H Mortazavi; M Izadi; AH Ehsani
Volume 7, Issue 1 , 2003, , Pages 14-18
Abstract
Background: Pityriasis rosea is an acute, inflammatory and self-limited disease, which is characterized by a primary scaly plaque (Herald patch) followed by a generalized, symmetrical papulosqumous eruption (Mostly on trunk and proximal extremities). Objective: To determine the efficacy of erythromycin ...
Read More
Background: Pityriasis rosea is an acute, inflammatory and self-limited disease, which is characterized by a primary scaly plaque (Herald patch) followed by a generalized, symmetrical papulosqumous eruption (Mostly on trunk and proximal extremities). Objective: To determine the efficacy of erythromycin in the treatment of patients with pityriasis rosea. Patients and Methods: In this double-blind randomized clinical trial, 46 patients with pityriasis rosea in two equal groups were treated with oral erythromycin 1gr per day or placebo for seven days and were followed 1, 2 and 6 weeks after treatment. The response to the treatment was evaluated as complete, partial and no response. Results: In 48% of the case group and 13% of the control group complete response was seen at the end of first week of treatment. Moreover, these rates reached 91% and 57% at the end of second week, 100% and 87% at the end of sixth week, respectively. The differences between two groups were statistically significant after first and second weeks. Conclusion: Oral erythromycin was effective in the treatment of patients with pityriasis rosea. Also, it reduces the duration of disease.